Latest News
Salix acquires additional intellectual property for rifaximin for reduction in risk of overt hepatic encephalopathy recurrence
19 September 2014 - Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Thursday the receipt of exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family from Cipla.

The grant covering rifaximin, which is on a worldwide basis, excludes the countries of Asia (other than Japan) and Africa, added Salix.

Under an amendment to the prior 2009 agreement, the patent rights covering amorphous rifaximin already licensed to Salix in the US, Canada and Mexico are now expanded to include certain patent rights in the EU, Japan, Australia, New Zealand and South Korea.

This agreement allows Salix to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement for the "Rifaximin Complexes" patent rights. Salix will pay royalties on net sales of products covered by the "Rifaximin Complexes" patents licensed to Salix.

Cipla's XIFAXAN (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age.

Login
Username:

Password: